Ott CJ, Federation AJ, Schwartz LS, et al. Enhancer Architecture and Essential Core Regulatory Circuitry of Chronic Lymphocytic Leukemia. Cancer Cell. 2018;34(6):982-995.e7. doi:10.1016/j.ccell.2018.11.001.
Mohr S, Doebele C, Comoglio F, et al. Hoxa9 and Meis1 Cooperatively Induce Addiction to Syk Signaling by Suppressing miR-146a in Acute Myeloid Leukemia. Cancer Cell. 2017;31(4):549-562.e11. doi:10.1016/j.ccell.2017.03.001.
Zhou F, Liu Y, Rohde C, et al. AML1-ETO requires enhanced C/D box snoRNA/RNP formation to induce self-renewal and leukaemia. Nat Cell Biol. 2017;19(7):844-855. doi:10.1038/ncb3563.
Pikman Y, Stegmaier K. Targeted therapy for fusion-driven high-risk acute leukemia. Blood. 2018;132(12):1241-1247. doi:10.1182/blood-2018-04-784157.
Meyer SE, Muench DE, Rogers AM, et al. miR-196b target screen reveals mechanisms maintaining leukemia stemness with therapeutic potential. J Exp Med. 2018;215(8):2115-2136. doi:10.1084/jem.20171312.
Hahn CK, Berchuck JE, Ross KN, et al. Proteomic and genetic approaches identify Syk as an AML target. Cancer Cell. 2009;16(4):281-94. doi:10.1016/j.ccr.2009.08.018.
Wang L, Shalek AK, Lawrence M, et al. Somatic mutation as a mechanism of Wnt/β-catenin pathway activation in CLL. Blood. 2014;124(7):1089-98. doi:10.1182/blood-2014-01-552067.
Landau DA, Clement K, Ziller MJ, et al. Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemia. Cancer Cell. 2014;26(6):813-25. doi:10.1016/j.ccell.2014.10.012.
Kalaitzidis D, Sykes SM, Wang Z, et al. mTOR complex 1 plays critical roles in hematopoiesis and Pten-loss-evoked leukemogenesis. Cell Stem Cell. 2012;11(3):429-39. doi:10.1016/j.stem.2012.06.009.
Chen C-W, Koche RP, Sinha AU, et al. DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia. Nat Med. 2015;21(4):335-43. doi:10.1038/nm.3832.